GLPwatch
Wegovy for Hair loss
semaglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCWegovy (semaglutide) is not FDA-approved for hair loss, and any use for this condition is off-label or investigational. Research includes reports of alopecia linked to semaglutide use, such as a disproportionality analysis from the FDA adverse event reporting system and a cohort study suggesting a potential risk of new-onset hair loss.
AI summary of the sources below.
| Drug | Wegovy (semaglutide) |
|---|---|
| Condition | Hair loss |
| Approval status | Investigational / off-label |
| Research papers | 4 |
Wegovy is not FDA-approved for hair loss; the research below reflects investigational or off-label study only.
Research on semaglutide for hair loss (4)
- Implications of Ozempic and Other Semaglutide Medications for Facial Plastic Surgeons.
- Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023.
- Letter to the Editor: Comment on Implications of Ozempic and Other Semaglutide Medications for Facial Plastic Surgeons.
- Risk of new-onset hair loss with semaglutide and tirzepatide: A TriNetX cohort study.